- Home
- WNEB vs ACHV Comparison
WNEB vs ACHV Comparison
Compare WNEB & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | ACHV |
|---|---|---|
| Founded | 1853 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 259.2M | 239.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | WNEB | ACHV |
|---|---|---|
| Price | $12.79 | $4.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $11.00 | ★ $15.50 |
| AVG Volume (30 Days) | 53.7K | ★ 546.8K |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ 27.15 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $79,080,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.48 | N/A |
| P/E Ratio | $19.60 | ★ N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $7.63 | $1.84 |
| 52 Week High | $13.95 | $5.78 |
Technical Indicators
Market Signals| Indicator | WNEB | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 53.16 | 49.28 |
| Support Level | $13.20 | $4.25 |
| Resistance Level | $13.51 | $4.56 |
| Average True Range (ATR) | 0.34 | 0.22 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 12.41 | 29.80 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.